MEDICAL THERAPY OF BENIGN PROSTATIC HYPERTROPHY

良性前列腺肥大的药物治疗

• 批准号: 6246877
• 负责人: HERBERT LEPOR
• 金额: $ 2.39万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-12 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246877
• 关键词: antihypertensive agents; benign prostate hyperplasia; biomarker; clinical research; clinical trials; drug screening /evaluation; finasteride; human subject; human therapy evaluation; pathologic process; ultrasonography

The primary objective is to ascertain if medical therapy with finasteride and or doxazocin delays or prevents the progression of BPH. Secondary objectives will include assessment of the natural history of BPH, maximal uroflow, symptom scores and medical outcomes. A subgroup of patients will undergo ultrasound, prostate biopsy, and serum hormonal determination in order to determine the histopathology of BPH and test existing biomarkers for their prognostic ability regarding response to therapy.

主要目的是确定是否使用芬氟拉明进行药物治疗 和/或多沙唑星延迟或预防BPH的进展。二次 目标将包括评估BPH的自然史，最大限度地 尿流、症状评分和医疗结果。一个亚组的患者将 接受超声波、前列腺活检和血清激素测定， 为了确定BPH的组织病理学和测试现有的生物标志物， 因为他们对治疗反应的预测能力。